Laurus Labs bags DRDO licence to develop and market covid drug
02 July 2021 | News
The company has applied with CDSCO for emergency use authorisation for 2DG
Image Credit: Shutterstock
Laurus Labs has received a licence from Defence Research & Development Organisation (DRDO) to manufacture and market 2- Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country.
Laurus Labs has already applied with CDSCO for emergency use authorisation (EUA) for 2DG.
